Replies to post #87 on Sharing Knowledge in Smallcaps

[streetshooter]

GNLB@1.84


Got inot this one late today. Liked the way the chart was setting up, the Indicators were saying a possible reversal was in the make. Stochastics and MACD are looking good, and the CCI is approaching a buy signal. Insiders are buying.

The company has a possible FDA approval in the works.

Will set stop around 1.68 or so. Hoping for at least a 30% gain on this one.

Genelabs, a biopharmaceutical company, focuses its research on the discovery of small molecule drugs that function by binding to DNA to regulate gene expression or inactive pathogens. For the six months ended 6/30/01, revenues fell 29% to $2.6 million. Net loss rose 3% to $6.5 million. Revenues reflect the completion of the U.S. Defense Advanced Research Projects Agency grant. Higher loss reflects preparation costs for the potential commercial introduction of Aslera.


Book Value (mrq*) $0.36
Earnings (ttm) -$0.26
Earnings (mrq) -$0.06
Sales (ttm) $0.11
Cash (mrq*) $0.54

Current Ratio (mrq*) 4.87
Debt/Equity (mrq*) 0.03
Total Cash (mrq) $23.5M

Market Capitalization $84.5M
Shares Outstanding 49.7M
Float 39.3M

The stock has support at 1.72 and 1.61. If the stock breaks down through support at 1.72 then it will probably continue lower to 1.61. The stock has resistance at 1.94 and at 2.23. If the stock breaks up through resistance at 1.94 then it will probably continue higher to 2.23. The 200-day moving average is at 2.76. This will also act as resistance. The stock has broken out of its long-term downtrend and is looking more positive recently. If the stock can form new support above 1.72 look for a rally to previous highs. The stock is slightly oversold according to the Stochastic Indicator (31.27

Insiders:

TITLE: Director
TRANSACTION: Purchase 100,000 11/07/01-11/28/01 $1.86-$1.96
OWNERSHIP: 145,162

7-Sep-01 GURWITH, MARC J
DRUG DEVELOPMENT 5,000
GNLB Purchased at $1.92 -- $1.98/Share.
Cost of $9,754.
21-Aug-01 DEWEY, THOMAS E
Director 10,000
GNLB Purchased at $1.40/Share.
Cost of $14,000.
24-Jul-01 GRAY, ARTHUR
Director 15,000
GNLB Purchased at $1.67/Share.
Cost of $25,050.
29-Jun-01 SMITH, JAMES
President, Director 5,526
GNLB Acquired at $1.33/Share.

[timhyma]

Charles, sold 1/2 my position on ADSX.

Looks like fire is going to move. What is you exit? I've been watching it, but did not enter.

[timhyma]

Charles, sold 1/2 my position on ADSX.

Looks like fire is going to move. What is your exit? I've been watching it, but did not enter.